⌕
Castle Biosciences · CSTL · Nasdaq
Tenet 55 · Mixed
Compare
$32.98+0.70%At closeTenet 55 · Mixed
$32.98+0.23 (+0.70%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Castle Biosciences (CSTL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CSTL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture

Regional honors in Houston, Arizona and Pittsburgh, national healthcare industry recognition and eight Culture Excellence awards bring Castle's 2026 Top Workplaces honors to 13 FRIENDSWOOD, Texas, Nov. 12, 2026 /PRNewswi…

CSTL +0.7% todayRead at source ↗
● PRNewsWireNov 11, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference

FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is sch…

CSTL +0.7% todayRead at source ↗
● PRNewsWireNov 11, 2026 · 07:00 ET
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas  Dermato-Onco2026 analysis supports the test's ability to provide individual…

CSTL +0.7% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:56 ET
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade

The consensus price target hints at a 37% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions c…

CSTL +0.7% todayRead at source ↗
● MarketBeatNov 5, 2026 · 22:17 ET
What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call

Castle Biosciences NASDAQ: CSTL raised its full-year revenue outlook after reporting 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test.…

CSTL +0.7% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 21:44 ET
Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript…

CSTL +0.7% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 18:46 ET
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.02 per share a year ago.…

CSTL +0.7% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Castle Biosciences Reports Third Quarter 2026 Results

Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million …

CSTL +0.7% todayRead at source ↗
● PRNewsWireOct 28, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is sch…

CSTL +0.7% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial r…

CSTL +0.7% todayRead at source ↗
● GuruFocusOct 12, 2026 · 19:59 ET
Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors

Castle Biosciences Valuation AssessmentOn October 12, 2026, Castle Biosciences Inc (CSTL) shares fell 4.8% to $32.76, marking a significant decline in the conte…

CSTL +0.7% todayRead at source ↗
● PRNewsWireOct 12, 2026 · 16:30 ET
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, In…

CSTL +0.7% todayRead at source ↗
● Defense WorldOct 6, 2026 · 10:40 ET
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling

Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) fell 6.1% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $34.48 and last traded at $34.4220. …

CSTL +0.7% todayRead at source ↗
● Defense WorldOct 2, 2026 · 06:10 ET
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock

Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Tobin Juvenal sold 1,034 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average pri…

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 30, 2026 · 16:30 ET
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) o…

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 28, 2026 · 07:00 ET
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing …

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 24, 2026 · 16:30 ET
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed int…

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 22, 2026 · 07:00 ET
Castle Biosciences to Open New Laboratory Facility in Scottsdale

New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: …

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 15, 2026 · 07:00 ET
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett's esophagus who later progress to cancer, while substantially reducing overuse o…

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 9, 2026 · 16:30 ET
JAAD Publication Shows Improved Performance of DecisionDx®-SCC

DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx-SCC's Class 1A (low risk) res…

CSTL +0.7% todayRead at source ↗
● PRNewsWireSep 8, 2026 · 09:30 ET
SciBase receives additional order from Castle Biosciences, advancing the collaboration

STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for …

CSTL +0.7% todayRead at source ↗
● Zacks Investment ResearchAug 28, 2026 · 13:01 ET
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.…

CSTL +0.7% todayRead at source ↗
● Zacks Investment ResearchAug 25, 2026 · 10:56 ET
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions…

CSTL +0.7% todayRead at source ↗
● PRNewsWireAug 20, 2026 · 07:00 ET
Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is sch…

CSTL +0.7% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just CSTL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.